Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Both sides next revision
mcgill_interdisciplinary_initiative_in_infection_and_immunity [2023/05/17 06:39]
liam
mcgill_interdisciplinary_initiative_in_infection_and_immunity [2023/05/19 19:53] (current)
liam
Line 10: Line 10:
  
 MI4 provided research funding related to [[COVID-19]] through their "MI4 Emergency COVID-19 Research Funding" program.((//Results of MI4 Emergency COVID-19 Research Funding.// MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding)) In particular, MI4 participated as a funding partner of the Canadian arm of the first [[randomized control trial]] (RCT) testing [[hydroxychloroquine]] for the post-exposure prevention of COVID-19, led by principal investigator [[David Boulware]], which began on March 17, 2020.((Lofgren, S. M., Nicol, M. R., Bangdiwala, A. S., Pastick, K. A., Okafor, E. C., Skipper, C. P., Pullen, M. F., Engen, N., Abassi, M., Williams, D. A., Nascene, A. A., Axelrod, M. L., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Cheng, M. P., Zarychanshi, R., Schwartz, I. S., & Silverman, M. J. (2020). //Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19.// medRxiv. https://doi.org/10.1101/2020.07.16.20155531)) MI4 provided research funding related to [[COVID-19]] through their "MI4 Emergency COVID-19 Research Funding" program.((//Results of MI4 Emergency COVID-19 Research Funding.// MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding)) In particular, MI4 participated as a funding partner of the Canadian arm of the first [[randomized control trial]] (RCT) testing [[hydroxychloroquine]] for the post-exposure prevention of COVID-19, led by principal investigator [[David Boulware]], which began on March 17, 2020.((Lofgren, S. M., Nicol, M. R., Bangdiwala, A. S., Pastick, K. A., Okafor, E. C., Skipper, C. P., Pullen, M. F., Engen, N., Abassi, M., Williams, D. A., Nascene, A. A., Axelrod, M. L., Lother, S. A., MacKenzie, L. J., Drobot, G., Marten, N., Cheng, M. P., Zarychanshi, R., Schwartz, I. S., & Silverman, M. J. (2020). //Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19.// medRxiv. https://doi.org/10.1101/2020.07.16.20155531))
 +
 +In December 2020, MI4 announced that it had received a $600,000 gift from [[pharmaceutical_companies:Pfizer]] via [[McGill University]] and the [[McGill University Health Centre Foundation]] towards the creation of the Pfizer Early Career Investigator Awards.((Clement, J., & Schwartz, T. (2020, December 4). //Pfizer Canada donation will help new researchers change the future.// McGill University Faculty of Medicine and Health Sciences. http://archive.today/2022.08.23-174216/https://www.mcgill.ca/medhealthsci/channels/news/pfizer-canada-donation-will-help-new-researchers-change-future-326710))
  
 ===== Organization ===== ===== Organization =====
Line 65: Line 67:
 ===== Activities ===== ===== Activities =====
  
 +^  MI4 Overcoming Barriers to COVID-19 Vaccination Research Funding Program((//Results of MI4 Overcoming Barriers to COVID-19 Vaccination Research Funding Program.// MI4. Retrieved May 17, 2023, from https://web.archive.org/web/20230517045026/https://www.mcgill.ca/mi4/mi4-supported-research/covid-19-vaccination-research-funding-program))  ^^
 +^ Lead investigators  ^ Project title  ^
 +| [[Nadine Kronfli]]  | The design, delivery, and evaluation of an educational intervention to increase COVID-19 vaccine uptake for incarcerated Canadian populations  |
 +| [[Inés Colmegna]]  | Preparing Adults for COVID-19 Vaccine – PROVIDE-A  |
 +| [[Zeev Rosberger]]  | Enhancing COVID-19 Vaccination Intentions by Eliciting Prosocial Altruistic Motives: Evaluating the Efficacy of a Brief Video-Based Intervention  |
 +| [[Ian Gold]]  | Overcoming COVID-19 [[Vaccine Hesitancy]]  |
 +| [[Abhinav Sharma]]  | COVID-19 Vaccination Among Cardiovascular Patients and High Risk Individuals (COVID-CPR): Identifying and Addressing Barriers in Quebec  |
 +| [[Moshe Ben-Shoshan]]  | COVERS: COVID Vaccine Evaluation of Resources and Solutions  |
 ^  MI4 Emergency COVID-19 Research Funding((//Results of MI4 Emergency COVID-19 Research Funding.// MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding))  ^^ ^  MI4 Emergency COVID-19 Research Funding((//Results of MI4 Emergency COVID-19 Research Funding.// MI4. Retrieved May 16, 2023, from https://web.archive.org/web/20230516234033/https://www.mcgill.ca/mi4/mi4-supported-research/emergency-covid-19-research-funding))  ^^
 ^  MI4 COVID-19 Strategic Funding Grants  ^^ ^  MI4 COVID-19 Strategic Funding Grants  ^^
Line 76: Line 86:
 | [[Dick Menzies]], [[Jonathon Campbell]]  | COVID-19 Targeted Community Testing  | | [[Dick Menzies]], [[Jonathon Campbell]]  | COVID-19 Targeted Community Testing  |
 | [[David Juncker]]  | Rapid and Sensitive Diagnostic Test for COVID-19 Using Saliva  | | [[David Juncker]]  | Rapid and Sensitive Diagnostic Test for COVID-19 Using Saliva  |
 +^  MI4 ECRF Round 1  ^^
 +| [[Matthew Cheng]], [[Leighanne Parkes]], [[Todd Lee]], [[Emily McDonald]]  | A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients in Canada (CATCO) |
 +| [[Matthew Cheng]], [[Erwin Schurr]], [[Guillaume Bourque]]  | Genomic biomarkers to predict outcome and treatment response in hospitalized COVID-19 patients  |
 +| [[Jörg H. Fritz]], [[Ciriaco Piccirillo]]  | Defining the protective host immune response to SARS-CoV-2  |
 +| [[John Hanrahan]]  | Targeting coronavirus cation channels with antiviral drugs  |
 +| [[Lara Khoury]], [[Alana Klein]], [[Marie-Eve Couture-Ménard]]  | Law in Pandemic Times: Powers and Accountability when Facing Emergency  |
 +| [[Irah King]]  | Targeting the gut microbiome to improve COVID-19 disease outcomes  |
 +| [[Todd Lee]], [[Emily McDonald]], [[Matthew Cheng]]  | Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial (COVID19 PEP RCT – Canada)  |
 +| [[Mathieu Maheu-Giroux]], [[Dimitra Panagiotoglou]], [[Alexandra Schmidt]], [[Nicole Basta]], [[David Buckeridge]], [[Yiqing Xia]], [[Arnaud Godin]], [[Dirk Douwes-Schultz]]  | Real-time modeling of COVID-19 transmission in Canada: epidemic intelligence for an effective public health response  |
 +| [[Sara Mahshid]]  | Colorimetric assisted microfluidic device for detection of SARS-Cov2 RNA  |
 +| [[Dick Menzies]], [[Jonathon Campbell]]  | Assessing costs and benefits of different testing strategies for COVID-19 in Canada  |
 +| [[Nicolas Moitessier]], [[Anthony Mittermaier]]  | PLpro as a target for the development of novel anti-COVID-19 agents  |
 +| [[Joaquin Ortega]], [[Duane Chung]], [[C. Perry Chou]]  | Development of a new [[Virus-like Particle]] (VLP) vaccine against COVID-19  |
 +| [[Martin Schmeing]], [[Don van Meyel]]  | Production of COVID-19 testing reagents to backstop and supplement existing sources  |
 +| [[Abhinav Sharma]]  | Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted in hospital with confirmed coronavirus disease (COVID-19) infection: The McGill RAAS-COVID-19 randomized controlled trial.  |
 +| [[Benjamin Smith]]  | PCR-based testing to shorten self-isolation duration in COVID-19 exposed healthcare workers  |
 +| [[Brett Thombs]], [[Linda Kwakkenbos]], [[Andrea Benedetti]], [[Susan Bartlett]], [[John Varga]], [[Scott Patten]], [[Nicole Culos-Reed]], [[Shannon Hebblethwaite]]  | Mental health in an at-risk population during COVID-19: longitudinal study of risk factors and outcomes and embedded trial of an activity, education, and support intervention  |
 ^  MI4 ECRF Round 2  ^^ ^  MI4 ECRF Round 2  ^^
 | [[Nicole Basta]]  | Real-Time Tracking of COVID-19 Vaccine Development  | | [[Nicole Basta]]  | Real-Time Tracking of COVID-19 Vaccine Development  |
Line 106: Line 133:
 | [[Charles Gladhill]]  | Ancient Narratives of Viral Contagion and the Aftermath of COVID-19  | | [[Charles Gladhill]]  | Ancient Narratives of Viral Contagion and the Aftermath of COVID-19  |
 | [[Warut Khern-am-nuai]]  | Helping Retailers and Customers to Cope with Surge Demands Under COVID-19  | | [[Warut Khern-am-nuai]]  | Helping Retailers and Customers to Cope with Surge Demands Under COVID-19  |
-| [[Anthony Masi]]  | Differences in Public Policy Responses and Citizens Reactions to the COVID-19 Pandemic: A Comparative Study of Canada, [[Sweden]], [[Italy]] and the [[south_korea|Republic of Korea]]  |+| [[Anthony Masi]]  | Differences in Public Policy Responses and Citizens Reactions to the COVID-19 Pandemic: A Comparative Study of [[Canada]], [[Sweden]], [[Italy]] and the [[south_korea|Republic of Korea]]  | 
 +| [[Ma'n Hilmi Mohammad Zawati]]  | Of Biobanking and Policy: Emerging Ethical and Legal Challenges During the COVID-19 Pandemic 
 +| [[Daiva Nielsen]]  | Experiences with Food Acquisition in Quebec During COVID-19 Pandemic: Risk Perceptions, Access Barriers, and Insight to Prepare for the Future 
 +| [[Juan Camilo Serpa]]  | Quebec Data Central for Impact of Covid-19 on Society and Business and for a Post-Pandemic World  |
  
 ===== External links ===== ===== External links =====
  
   * [[https://www.mcgill.ca/mi4/|Website]]   * [[https://www.mcgill.ca/mi4/|Website]]
Back to top